普莱柯生物工程股份有限公司 2024 年第三次临时股东大会会议资料 普莱柯生物工程股份有限公司 2024 年第三次临时股东大会会议资料 4、股东及股东代表参加本次会议，依法享有发言权、质询权、表决权等各 项权利。股东事先准备发言的，应当先向会务组登记。股东不得无故中断股东大 会议程要求发言。本次会议在进行表决时，股东及股东代表不可进行大会发言。 二 O 二四年九月 普莱柯生物工程股份有限公司 2024 年第三次临时股东大会会议资料 普莱柯生物工程股份有限公司 2024 年第三次临时股东大会会议须知 为维护投资者的合法权益，确保普莱柯生物工程股份有限公司（以下简称"公 司"）2024 年第三次临时股东大会的正常秩序和议事效率，根据《中华人民共和 国公司法》《上市公司股东大会规则》《公司章程》《公司股东大会议事规则》的 有关规定，特制定本次股东大会会议须知： 一、会议组织 1、公司负责本次会议的程序安排和会务工作，出席会议人员应当听从工作 人员安排，共同维护好会议秩序。 2、为保证本次会议的正常秩序，除出席会议的股东及股东代表、董事、监 事、董事会秘书、高级管理人员以及见证律师以外，公司有权拒绝其他人员进入 会场 ...

根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，现将公司回购进展情况公告如下： 证券代码：603566 证券简称：普莱柯 公告编号：2024-046 普莱柯生物工程股份有限公司 关于股份回购进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： | 回购方案首次披露日 | 2023 年 | 11 月 | 14 日 | | --- | --- | --- | --- | | 回购方案实施期限 | | | 自董事会审议通过之日起不超过 12 个月 | | 预计回购金额 | 6,000 | 万元~12,000 | 万元 | | 回购用途 | | | 用于员工持股计划或股权激励 | | 累计已回购股数 | 414.29 | 万股 | | | 累计已回购股数占总股本比例 | 1.20% | | | | 累计已回购金额 | 6,032.82 | 万元 | | | 实际回购价格区间 | 11.66 | 元/股~22.48 | 元/股 | 一、回购股份的基本情况 普莱柯生物工程股份有限公司（简 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has a sufficient reserve of new products and continues to grow, with high pig prices awaiting performance recovery [1] - The company reported a revenue of 483 million yuan for H1 2024, a year-on-year decrease of 21.82%, and a net profit of 74 million yuan, down 36.28% year-on-year [1] - Due to intensified competition in the animal health industry, the profit forecast for 2024-2026 has been revised downwards [1] - The company emphasizes research and development, with a strong pipeline of new products and a focus on large clients for sustained growth [1] Financial Performance Summary - For H1 2024, the revenue from biological products was 355 million yuan (down 12.56% year-on-year), with a gross profit of 240 million yuan and a gross margin of 67.72% [2] - Revenue from pig vaccines was 147 million yuan (down 30.17% year-on-year), while revenue from poultry vaccines was 199 million yuan (up 2.79% year-on-year) [2] - The company’s R&D expenses for H1 2024 were 43 million yuan, accounting for 8.89% of revenue, reflecting an increase of 8.27% year-on-year [3] - The company’s net profit for 2024 is projected to be 167 million yuan, with EPS of 0.48 yuan, and the corresponding P/E ratios for 2024-2026 are 25.5, 21.1, and 18.4 respectively [4]

普莱柯生物工程股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账情况 根据公司 2021 年第二次临时股东大会决议，并经中国证券监督管理委员会 证监许可〔2022〕1251 号《关于核准普莱柯生物工程股份有限公司非公开发行 股票的批复》核准，核准公司非公开发行不超过 64,299,200.00 股新股。本公司 实际向发行对象非公开发行人民币普通股（A 股）股票 31,420,573.00 股，发行 价格 28.58 元/股，募集资金总额为 897,999,976.34 元，扣除不含税发行费用 12,179,453.12 元，募集资金净额为人民币 885,820,523.22 元。上述资金于 2022 年 9 月 5 日全部到位，已经立信会计师事务所（特殊普通合伙）审验，并出具信 会师报字〔2022〕第 ZA15752 号《验资报告》。 （二）募集资金使用情况 2024 年 1-6 月，公司募集资金使用金额 ...

Financial Performance - The company reported a revenue increase of 15% year-over-year for the first half of 2024, reaching approximately 1.2 billion CNY[7]. - The company has set a revenue guidance of 2.5 billion CNY for the full year 2024, representing a 10% increase compared to 2023[7]. - The company's operating revenue for the first half of 2024 was CNY 483.15 million, a decrease of 21.82% compared to CNY 617.98 million in the same period last year[12]. - Net profit attributable to shareholders was CNY 73.95 million, down 36.28% from CNY 116.05 million year-on-year[12]. - The net profit after deducting non-recurring gains and losses was CNY 66.40 million, a decline of 46.13% compared to CNY 123.27 million in the previous year[12]. - The company's cash flow from operating activities was CNY 48.15 million, a decrease of 35.25% from CNY 74.37 million in the same period last year[12]. - Total revenue for the first half of 2024 was approximately ¥478.75 million, a decrease of 21.69% compared to the previous year[49]. - The company reported a total comprehensive income for the first half of 2024 of CNY 73,946,259.88, down 36.25% from CNY 116,048,607.53 in the first half of 2023[111]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, totaling 500,000 users by the end of June 2024[7]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[7]. - The company is focusing on technological innovation and market expansion to enhance its competitiveness in a highly competitive veterinary medicine market[19]. Product Development and Innovation - New product development includes the launch of a novel vaccine, which is currently in the clinical trial phase, expected to be completed by Q4 2024[7]. - The company is actively developing new vaccines for pig diseases, focusing on porcine epidemic diarrhea and porcine reproductive and respiratory syndrome, aiming for significant market expansion in the pig vaccine sector[29]. - The company is launching a new cat trivalent inactivated vaccine in 2024, which has received market recognition for its high efficiency and safety, contributing to the growth of the pet vaccine and pharmaceutical sector[31]. - The company has established multiple national-level research platforms, accumulating 64 new veterinary drug registration certificates and submitting 570 invention patent applications, with 322 granted[39]. Financial Position and Assets - The company has maintained a strong cash position with over 500 million CNY in liquid assets as of June 2024[7]. - The total assets at the end of the reporting period were CNY 3.10 billion, down 4.84% from CNY 3.26 billion at the end of the previous year[12]. - The company's net assets attributable to shareholders decreased by 3.56% to CNY 2.63 billion from CNY 2.72 billion at the end of the previous year[12]. - Cash and cash equivalents at the end of the period amounted to ¥357.82 million, representing 11.53% of total assets, an increase of 12.80% year-over-year[49]. Risks and Compliance - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[2]. - The company faces risks from animal epidemics, regulatory changes, and intensified market competition, which could impact operational performance[56][57][58]. - The company emphasizes compliance and innovation to mitigate risks and enhance operational performance[57][58]. - The company has established environmental monitoring and pollution control facilities, ensuring compliance with relevant regulations[66]. Shareholder and Governance - The company did not propose any profit distribution or capital reserve transfer plans for the reporting period[62]. - The company has committed to not engaging in any business activities that compete with its existing operations during the tenure of its controlling shareholder, Zhang Xuke[72]. - The company guarantees to compensate investors for any losses incurred due to false statements or omissions in its prospectus[76]. - The company has not reported any non-operating fund occupation by major shareholders or related parties during the reporting period[81]. Research and Development - Research and development expenses increased by 8.27% to CNY 42.95 million, driven by clinical trial costs and depreciation of the newly established biosafety laboratory[47]. - The company is leveraging advanced technologies to improve product quality, utilizing high-density fermentation and protein purification techniques to enhance vaccine efficacy and reduce side effects[40]. Environmental Responsibility - The company has implemented emergency response plans for environmental incidents, conducting regular training and drills for employees[68]. - The company has maintained a strong commitment to environmental responsibility, with all pollution control equipment operating effectively[66]. Accounting and Financial Reporting - The company follows the accounting standards set by the Ministry of Finance, ensuring that financial statements reflect the true financial status and operating results[133]. - The company’s accounting period runs from January 1 to December 31 each year[134]. - The company has not made any significant changes to accounting policies or estimates in the current reporting period[197].

证券代码：603566 证券简称：普莱柯 公告编号：2024-041 普莱柯生物工程股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 普莱柯生物工程股份有限公司（以下简称"公司"）将于 2024 年 8 月 30 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 9 月 3 日下午 16:00-17:00 举 行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 董事、总经理：胡伟先生 董事、董事会秘书：赵锐先生 董事、财务总监：裴莲凤女士 独立董事：曹永长先生 四、投资者参加方式 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 会议召开时间：2024 年 9 月 3 日（星期二）下 ...

证券代码：603566 证券简称：普莱柯 公告编号：2024-040 普莱柯生物工程股份有限公司 | 6 | 银行结构性存款 | 10,00.00 | 10,00.00 | 8.14 | 0 | | --- | --- | --- | --- | --- | --- | | 7 | 银行结构性存款 | 196,00.00 | 196,00.00 | 135.32 | 0 | | 8 | 银行结构性存款 | 18,00.00 | 18,00.00 | 3.68 | 0 | | 9 | 银行结构性存款 | 197,00.00 | 197,00.00 | 20.24 | 0 | | 10 | 银行结构性存款 | 33,00.00 | 33,00.00 | 22.10 | 0 | | 11 | 银行结构性存款 | 13,00.00 | 13,00.00 | 8.70 | 0 | | 12 | 银行结构性存款 | 197,00.00 | 197,00.00 | 65.31 | 0 | | 13 | 银行结构性存款 | 45,00.00 | 45,00.00 | 4.93 | 0 | | 14 | 银行结构性存款 | 1 ...

证券代码：603566 证券简称：普莱柯 公告编号：2024-039 普莱柯生物工程股份有限公司 关于以集中竞价交易方式回购公司股份比例达 1%的 进展公告 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，公司在回购期间，回购股份占上市公司总股本的比例每增加 1%的，应当 在事实发生之日起 3 个交易日内予以披露，现将公司回购股份的进展情况公告如 下： 截至 2024 年 8 月 19 日，公司通过集中竞价交易方式已累计回购股份 362.47 万股，占公司当前总股本的比例为 1.05%，与上次披露数相比增加 0.143%，回 购的最高价为 22.48 元/股、最低价为 11.93 元/股，已支付的总金额为 54,235,340 元（不含交易费用）。上述回购符合法律法规的有关规定和公司回购股份方案的 要求。 三、其他事项 重要提示： | 回购方案首次披露日 | 2023 年 | 11 月 | 14 | 日 | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | | | | 自董事会审议通过之日起不超过 | 12 个月 | | 预 ...

证券代码：603566 证券简称：普莱柯 公告编号：2024-038 普莱柯生物工程股份有限公司 关于股份回购进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 一、回购股份的基本情况 普莱柯生物工程股份有限公司（简称"公司"）于 2023 年 11 月 13 日召开 第五届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司股份 的议案》，同意公司使用自有资金以集中竞价交易的方式回购公司股份，拟用于 实施股权激励及/或员工持股计划；回购股份资金总额不低于人民币 6,000 万元 （含）且不超过人民币 1.2 亿元（含），回购价格不超过人民币 30.00 元/股（含）， 实施期限为自董事会审议通过回购股份方案之日起不超过 12 个月。上述事项具 体内容详见公司于 2023 年 11 月 14 日在上海证券交易所网站（www.sse.com.cn） 披露的相关公告（公告编号：2023-044）。 二、回购股份的进展情况 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定， ...

证券代码：603566 证券简称：普莱柯 公告编号：2024-037 普莱柯生物工程股份有限公司 关于子公司获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）全资子公司洛阳惠中兽药有 限公司（以下简称"惠中兽药"）与其他单位联合申报的"环孢素内服溶液"为 新兽药，并于 2024 年 7 月 31 日公示了核发《新兽药注册证书》（中华人民共和 国农业农村部公告第 812 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：环孢素内服溶液 注册分类：五类 三、新兽药上市前仍需履行的程序 按照《兽药管理条例》《兽药产品批准文号管理办法》等相关规定，该产品 在上市之前，还应取得农业农村部核发的兽药产品批准文号。 四、新兽药开发成功对公司的影响 该新兽药证书的取得是公司瞄准宠物赛道，持续重视科技创新、不断加大宠 物产品开发投入的结果。该产品打破了国外环孢素内服溶液在国内的垄断地位， 是公司宠物用化 ...